首页> 外国专利> METHOD FOR PREDICTING TREATMENT EFFICACY IN PATIENTS WITH RECURRENT PULMONARY TUBERCULOSIS

METHOD FOR PREDICTING TREATMENT EFFICACY IN PATIENTS WITH RECURRENT PULMONARY TUBERCULOSIS

机译:预测复发性肺结核患者治疗效果的方法

摘要

A method for predicting the treatment efficacy in the patients with recurrent pulmonary tuberculosis consists in assessing the termination of mycobacteria isolation, recession of focal infiltrative changes, and the healing of the cavitary lesions in the lungs. At the beginning and at the end of the intensive phase of antituberculous therapy, CD3+, CD4+, CD8+, CD16+, CD19+ lymphocyte subpopulations are assessed by immunofluorescence with monoclonal antibodies. The increase in CD8+, CD16+ and CD19+ counts by more than 9 % and CD3+ and CD4+ counts by more than 12 % relative to the initial values suggests the positive treatment effect. The absence of the corresponding dynamics suggests the insufficient treatment efficacy. In such cases, antituberculous therapy is considered to be continued for extra two months.
机译:预测复发性肺结核患者治疗效果的方法包括评估分枝杆菌分离的终止,局灶性浸润性改变的退缩以及肺部空洞病变的愈合。在抗结核治疗强化阶段的开始和结束时,通过单克隆抗体的免疫荧光评估CD3 +,CD4 +,CD8 +,CD16 +,CD19 +淋巴细胞亚群。相对于初始值,CD8 +,CD16 +和CD19 +计数增加了9%以上,CD3 +和CD4 +计数增加了12%以上,表明治疗效果良好。没有相应的动力学提示治疗效果不足。在这种情况下,抗结核治疗被认为可以再持续两个月。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号